Business
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 at 2:20 p.m. ETCompany to host webcast on Monday, February 10, 2025 at 8:00 a.m. ET to discuss the 4D-150 interim data including recently diagnosed subgroup, which most resembles the Phase 3 4FRONT-1 and -2 patient populations EMERYVILLE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that the Company will present the initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (wet AMD) patient population at Angiogenesis, Exudation, and Degeneration 2025 being held virtually on February 8, 2025. The Company will host a webcast to discuss the PRISM interim data and additional analyses from the 4D-150 program in wet AMD and diabetic macular edema (DME) on Monday, February 10, 2025 at 8:00 a.m. ET. Dante Pieramici, M.D. and Veeral Sheth, M.D., MBA, FACS, FASRS, Principal Investigators in the PRISM clinical trial, will also present on the webcast and be available for Q&A. Angiogenesis, Exudation, and Degeneration 2025 Presentation Details: Title:Phase 2b Population Extension Cohort Evaluating 4D-150 in Neovascular Age-Related Macular Degeneration: 52-Week ResultsDate/Time:Saturday, February 8, 2025 (2:20 – 2:30 p.m. ET)Presenter:Dante Pieramici, M.D., California Retina Consultants, Santa Barbara, CA The presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications Corporate Webcast Details Title:4D-150 in Broad Wet AMD Population: Interim 52-week Data from Phase 2b & Program Durability Update for 3E10 vg/eye (Phase 3 Dose)Date/Time:Monday, February 10, 2025 at 8:00 a.m. ETKOL Panelists: Dante Pieramici, M.D., California Retina Consultants, Santa Barbara, CAVeeral Sheth, M.D., MBA, FACS, FASRS, University Retina and Macula Associates, Chicago, IL Topics: 52-week landmark interim efficacy data for 3...